Cosmetic Specialties 34 Cosmetic Specialties

Total Page:16

File Type:pdf, Size:1020Kb

Cosmetic Specialties 34 Cosmetic Specialties cosmetic specialties 34 cosmetic specialties PRODUCT INCI NAME USAGE TOCOPHERYL ACETATE, ASCORBYL PALMITATE, RETINYL PALMITATE, NIACINAMIDE, Anti-oxidant, anti-radical, moisturizing, anti-seborrheic, anti-inflammatory and slim- 10 VITAMIN COMPLEX PANTHENOL, PYRIDOXINE ming. HCL, INOSITOL, BIOTIN, THIAMINE HCL, RIBOFLAVIN TOCOPHERYL ACETATE, RETINYL PALMITATE, A+B5+B8+E+F VITAMIN ETHYL LINOLEATE, ETHYL Intended for skin and nails care. COMPLEX LINOLENATE, PANTHENOL, INOSITOL, ETHYL OLEATE TOCOPHERYL ACETATE, A+C+E VITAMIN COMPLEX ASCORBYL PALMITATE, Skin protective. AND BIOFLAVONOIDS RETINYL PALMITATE, BIOFLAVONOIDS CHOLECALCIFEROL, TOCOPHERYL ACETATE, RETINYL PALMITATE, A+D+E+F VITAMIN COMPLEX Treatments intended for skin and nails restoring care. ETHYL LINOLEATE, ETHYL LINOLENATE, ETHYL OLEATE GLYCINE SOJA GERM EXTRACT, ALGAE EXTRACT, ABDOMINAL FIRMING HYDROLYZED ELASTIN, It favours the skin metabolism and gives a tightening effect. COMPLEX RETINYL PALMITATE, ASCORBYL PALMITATE, TOCOPHERYL ACETATE LACTIC ACID, GLYCOLIC ACID, SODIUM ALPHA-HYDROXYACIDS HYDROXIDE, MALIC ACID, Exfolliant, lightener. BLEND TARTARIC ACID, CITRIC ACID LACTIC ACID, GLYCOLIC ACID, SODIUM ALPHA-HYDROXYACIDS HYDROXIDE, MALIC ACID, Exfolliant, lightener. BLEND + VITAMIN A TARTARIC ACID, CITRIC ACID, RETINYL PALMITATE FAEX EXTRACT, HUMULUS LUPULUS EXTRACT, SALVIA OFFICINALIS LEAF EXTRACT, CUCUMIS SATIVUS EXTRACT, HYDROLYZED ANTI-ACNE COMPLEX KERATIN, ADENOSINE Treatment for acneic skins. Very appropriate in preparations for seborrheic skins. TRIPHOSPHATE, TIOXOLONE, NIACINAMIDE, PANTHENOL, RIBOFLAVIN, INOSITOL, THIAMINE HCL, BIOTIN, PYRIDOXINE HCL, CYANOCOBALAMIN 35 cosmetic specialties PRODUCT INCI NAME USAGE CHAMOMILLA RECUTITA EXTRACT, FAEX EXTRACT, BETULA ALBA LEAF EXTRACT, HAMAMELIS VIRGINIANA LEAF EXTRACT, MALVA SYLVESTRIS EXTRACT, SAMBUCUS NIGRA FLOWER EXTRACT, CALENDULA OFFICINALIS FLOWER EXTRACT, TILIA CORDATA EXTRACT, SILYBUM MARIANUM ANTI-REDNESS COMPLEX EXTRACT, AESCULUS Treatment for skin with redness, telangiectasias, couperose and rosacea. HIPPOCASTANUM EXTRACT, TIOXOLONE, TOCOPHERYL ACETATE, ASCORBYL PALMITATE, PIROCTONE OLAMINE, RETINYL PALMITATE, NIACINAMIDE, PANTHENOL, RIBOFLAVIN,BIOTIN, THIAMINE HCL, PYRIDOXINE HCL, INOSITOL, CYANOCOBALAMIN HYDROLYZED ELASTIN, PANAX GINSENG ROOT EXTRACT, CERATONIA SILIQUA SEED EXTRACT, It is used in preparations to obtain an immediate and temporary effect of cutaneous ANTI-SAGGING COMPLEX EQUISETUM ARVENSE firmners. Furthermore, in products for the treatment of ageing effects, with increase LEAF EXTRACT, of skin flabbiness and appearance or increase of wrinkles. HUMULUS LUPULUS EXTRACT, ADENOSINE TRIPHOSPHATE CENTELLA ASIATICA EXTRACT, GLYCOSAMINOGLYCANS, It gives to the skin a renewed elasticity and vitality, at the same time, it increases ANTI-STRETCH COMPLEX TOCOPHERYL ACETATE, skin moisturizing. ASCORBYL PALMITATE, RETINYL PALMITATE FAEX EXTRACT, CARICA PAPAYA FRUIT EXTRACT, Complex with dermo-purifying, regulator of the sebaceous and anti-acneic glands BIOGRÜNDL ANTIFAT GLYCINE SOJA GERM properties. Appropriate for the treatment of oily, seborrheic, impure or acneic skins. EXTRACT CAMELlIA SINENSIS LEAF EXTRACT, GINKGO BILOBA Ideal to include in preparations with anti-oxidant and protective properties. Stimulat- BIOGRÜNDL ANTIOX LEAF EXTRACT, GLYCINE ing of the microcirculation in the skin tissue, sun protector and anti-wrinkle. SOJA GERM EXTRACT VITIS VINIFERA FRUIT EXTRACT, PYRUS MALUS BIOGRÜNDL EXFOLIANT It has lightening and exfoliant properties. FRUIT EXTRACT, CITRUS LIMON FRUIT EXTRACT HYDROLYZED ELASTIN, FAEX EXTRACT, BODY FIRMING COMPLEX Body treatments of modelling, massage and firming of flabby areas. HAMAMELIS VIRGINIANA LEAF EXTRACT HUMULUS LUPULUS EXTRACT, SALVIA BUST FIRMING COMPLEX OFFICINALIS LEAF Turgidity and tightening effect in bust treatments. EXTRACT, HAMAMELIS VIRGINIANA LEAF EXTRACT 36 cosmetic specialties PRODUCT INCI NAME USAGE TOCOPHERYL ACETATE, It helps wounds, and sores healing, also, in the treatment of bruises, in skin spots C+PP+E VITAMIN COMPLEX ASCORBYL PALMITATE, and hyper-coloration. NIACINAMIDE HELIANTHUS ANNUUS SEED OIL, THEOBROMA It is advisable for chocotherapy products, also in skin protectors against the envi- CACAO EXTRACT, ronment, anti-solar preparations, relaxing treatments, anti-stress preparations, face CHOCO-ENAR THEOBROMA CACAO and body masks, perspiration paraffin and lipsticks. Likewise, it is also advisable for SEED BUTTER, GLYCERYL dry, aged or atonic skin products. STEARATE, PARFUM HELIANTHUS ANNUUS SEED OIL, GLYCERYL Recommended for anti-aging, and after-sun preparations. Likewise, for anti-stress COFFEE-ENAR STEARATE, COFFEA treatments. Also, used in lipsticks, products for dry, aged and atonic skins. ARABICA EXTRACT, PARFUM CAMPHOR, MENTHOL, COLD EFFECT RELAX ROSMARINUS OFFICINALIS It relieves muscle tension and strengthens tissues. Stiffness treatment. CONCENTRATE EXTRACT, EUCALYPTUS GLOBULUS LEAF EXTRACT THYMUS EXTRACT, Skin regenerative, wrinkles and expression lines, rejuvenating, influence over the CYTOKINE COMPLEX PLACENTAL PROTEIN hair growth, slows hair loss. FARNESOL, MENTHA PIPERITA EXTRACT, LAVANDULA ANGUSTIFOLIA DEO-CONTROL COMPLEX EXTRACT, SALVIA Deodorant. OFFICINALIS LEAF EXTRACT, ROSMARINUS OFFICINALIS EXTRACT LACTIC ACID, GLYCOLIC ACID, MALIC ACID, TARTARIC ACID, CITRIC ACID, HIBISCUS DEPIGMENTING COMPLEX SABDARIFFA FLOWER Depigmenting, soft exfoliant. EXTRACT, KOJIC ACID, ARCTOSTAPHYLOS UVA URSI LEAF EXTRACT, SODIUM HYDROXIDE LACTIC ACID, GLYCOLIC ACID, MALIC ACID, TARTARIC ACID, CITRIC ACID, HIBISCUS DEPIGMENTING COMPLEX + SABDARIFFA FLOWER Depigmenting effect, soft exfoliant. VITAMIN C EXTRACT, KOJIC ACID, ARCTOSTAPHYLOS UVA URSI LEAF EXTRACT, ASCORBYL PALMITATE, SODIUM HYDROXIDE JASONIA GLUTINOSA EXTRACT, ALOE BARBADENSIS LEAF EXTRACT, HAMAMELIS VIRGINIANA LEAF DEPIL RETARD Retardant for body hair growth. EXTRACT, CETRIMONIUM CHLORIDE, LAURYL ISOQUINOLINIUM BROMIDE, SALICYLIC ACID, MENTHOL 37 cosmetic specialties PRODUCT INCI NAME USAGE HAMAMELIS VIRGINIANA LEAF EXTRACT, MALVA SYLVESTRIS FLOWER / It balances the cutaneous pH, decongests the skin, softents the skin and makes it DRY SKIN TONIC LOTION LEAF EXTRACT, more resistant to the negative environmental effects. CHAMOMILLA RECUTITA EXTRACT, TILIA CORDATA EXTRACT, ALLANTOIN GLYCERYL STEARATE, C12-20 ACID PEG- EMULGAR BG-7 EMULSIFIER Non-ionic emulsifier. 8 ESTER, CETYL PHOSPHATE HYDROLYZED COLLAGEN, HYDROLYZED ELASTIN, ADENOSINE TRIPHOSPHATE, PANAX ENZIMATIC MODIFIERS Cutaneous revitalizer, protein maker, delays ageing, collagenases inhibitor. GINSENG ROOT EXTRACT, ECHINACEA ANGUSTIFOLIA EXTRACT, FUCUS VESICULOSUS EXTRACT HELIANTHUS ANNUUS SEED OIL, OLEA EUROPAEA FRUIT OIL, Its use is particularly suitable for strengthening, regenerating, repairing, protec- ZEA MAYS GERM OIL, EYELASH COMPLEX tive and longthen properties of eyelashes, applied directly or incorporated in other VITIS VINIFERA SEED OIL, preparations, in particular, in masks. ROSA CANINA FRUIT OIL, DECYL OLEATE, RICINUS COMMUNIS SEED OIL CINNAMOMUM ZEYLANICUM BARK EXTRACT, ARNICA HEAT EFFECT RELAX MONTANA FLOWER It keeps thermal regulation and increases blood irrigation in the area of application, CONCENTRATE EXTRACT, CAMPHOR, it strengthens tissues. MENTHOL, METHYL SALICYLATE, METHYL NICOTINATE Nutritive, regenerative, protector, hydrating. It accelerates healing of wounds and HYDROLYZED COLLAGEN HYDROLYZED COLLAGEN burns. HYDROLYZED CORN HYDROLYZED CORN Moisturizing, conditioner, protector, softener. It reduces the irritant effect of sur- PROTEINS PROTEIN factants noticeably. Nutritious, regenerating, protective and moisturizing. Accelerates healing of wounds HYDROLYZED ELASTIN HYDROLYZED ELASTIN and burns. Protects skin and hair against the attack of alkalis, detergents and harmful environmental agents. HYDROLYZED OAT PROTEIN, HYDROLYZED HYDROLYZED FOUR High sustantivity with skin and hair, repair action, bioestimulant and protecting. It CORN PROTEIN, VEGETABLE PROTEINS (OAT, can be employed in capillary preparations, in skin treatment, because of its hydrat- HYDROLYZED SOY CORN, SOY AND WHEAT) ing, elasticizer, anti-wrinkle and vitalizing actions. PROTEIN, HYDROLYZED WHEAT PROTEIN Nutritive, regenerative, protector, hydrating. It accelerates healing of wounds and HYDROLYZED MARINE ALGAE EXTRACT burns. It protects skin and hair against the attack of alkalis, detergents, and from ELASTIN harmful environmental agents. HYDROLYZED MILK HYDROLYZED MILK Nutritive, repairing, skin protector. It presents intermediate properties between an- PROTEINS PROTEIN imal and vegetable origin proteins. HYDROLYZED OAT PROTEINS HIDROLYZED OAT PROTEIN Moisturizing, elasticizing, anti-wrinkle and vitalizing. Restructuring, cutaneous metabolism enhancer. Minimizes the damage caused by HYDROLYZED PEA PROTEINS PISUM SATIVUM EXTRACT UV radiation and other unfavorable external factors on the skin. 38 cosmetic specialties PRODUCT INCI NAME USAGE It nourishes and restores skin tissue, powerful anti-wrinkle, hydrates deeply, (epi- HYDROLYZED RICE HYDROLYZED RICE PROTEINS dermis and dermis) it produces a film over the skin that protects and elastizes skin, EXTRACT giving an immediate tensor effect, emollient and softening. Treatment for hair, it excerts a nutritious and protective action on the capillary fiber, HYDROLYZED SILK PROTEINS HYDROLYZED SILK it provides hydration and restoring. It can substitute animal origin proteins, even with advantage. In cosmetic and der- HYDROLYZED SOY HYDROLYZED SOY PROTEINS matological preparations,
Recommended publications
  • Novel Derivatives of Bio-Affecting Phenolic Compounds and Pharmaceutical Composition Containing Them
    Europaisches Patentamt European Patent Office © Publication number: 0046 270 A1 Office europeen des brevets ™ EUROPEAN PATENT APPLICATION @ Application number: 81106277.7 © Int. CI.3: C 07 C 103/78, C 07 C 93/26, C 07 C 69/24, C 07 C 1 53/07, @ Date of filing: 12.08.81 C07C 69/28 // C07C1 25/065 <§) Priority: 13.08.80 US 177825 © Applicant: INTERx RESEARCH CORPORATION, 2201 West 21 st Street, Lawrence Kansas 66044 (US) © I nventor : Bodor, Nicholas S., 31 5 Southwest 91 st Street, ® Dateofpublicationofapplication:24.02.82 S^^S^mHariMBM Bulletin m/b Terrace, Gainesville, Florida 32605 (US) Inventor: Pogany, Stefano A., 520 Louisiana Street, Lawrence Kansas 66044 (US) @ Designated Contracting States : AT BE CH DE FR GB IT ® Representative: Abitz, Walter, Dr.-lng. et al, Abitz, Mori, LI LU NL SE Gritschneder P.O. Box 86 01 09, D-8000 Munchen 86 (DE) Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them. Novel@ Novel transient prodrug forms of bio-affecting phe- amyl, CH2ONO2,CH2ON02, -CH2OCOR2 or any non-heterocyclic nolic compounds are selected from the group consisting of member of the group defined by R2Rz above; and n.isn is at least those having the structural formula (I): one and equals the total number of phenolic hydroxyl functions comprising the non-steroidal bioaffecting phenol o etherified via a R2COXCH(R3)0-moiety; those having the structural formula (II): R2-C-X-CH-0- (I) I O R, II R2-C-X-CH-0- -RM-i-O-C-R2 (II) wherein X is O, S or NR5 wherein R5 is hydrogen or lower alkyl;alky!;
    [Show full text]
  • Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr
    Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,026,285 B2 Bezwada (45) Date of Patent: Sep
    US008O26285B2 (12) United States Patent (10) Patent No.: US 8,026,285 B2 BeZWada (45) Date of Patent: Sep. 27, 2011 (54) CONTROL RELEASE OF BIOLOGICALLY 6,955,827 B2 10/2005 Barabolak ACTIVE COMPOUNDS FROM 2002/0028229 A1 3/2002 Lezdey 2002fO169275 A1 11/2002 Matsuda MULT-ARMED OLGOMERS 2003/O158598 A1 8, 2003 Ashton et al. 2003/0216307 A1 11/2003 Kohn (75) Inventor: Rao S. Bezwada, Hillsborough, NJ (US) 2003/0232091 A1 12/2003 Shefer 2004/0096476 A1 5, 2004 Uhrich (73) Assignee: Bezwada Biomedical, LLC, 2004/01 17007 A1 6/2004 Whitbourne 2004/O185250 A1 9, 2004 John Hillsborough, NJ (US) 2005/0048121 A1 3, 2005 East 2005/OO74493 A1 4/2005 Mehta (*) Notice: Subject to any disclaimer, the term of this 2005/OO953OO A1 5/2005 Wynn patent is extended or adjusted under 35 2005, 0112171 A1 5/2005 Tang U.S.C. 154(b) by 423 days. 2005/O152958 A1 7/2005 Cordes 2005/0238689 A1 10/2005 Carpenter 2006, OO13851 A1 1/2006 Giroux (21) Appl. No.: 12/203,761 2006/0091034 A1 5, 2006 Scalzo 2006/0172983 A1 8, 2006 Bezwada (22) Filed: Sep. 3, 2008 2006,0188547 A1 8, 2006 Bezwada 2007,025 1831 A1 11/2007 Kaczur (65) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2009/0076174 A1 Mar. 19, 2009 EP OO99.177 1, 1984 EP 146.0089 9, 2004 Related U.S. Application Data WO WO9638528 12/1996 WO WO 2004/008101 1, 2004 (60) Provisional application No. 60/969,787, filed on Sep. WO WO 2006/052790 5, 2006 4, 2007.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2003/0068365A1 Suvanprakorn Et Al
    US 2003.0068365A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0068365A1 Suvanprakorn et al. (43) Pub. Date: Apr. 10, 2003 (54) COMPOSITIONS AND METHODS FOR Related U.S. Application Data ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME BEADS (60) Provisional application No. 60/327,643, filed on Oct. 5, 2001. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); Tanusin Ploysangam, Bangkok (TH); Publication Classification Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok (51) Int. Cl." .......................... A61K 9/127; A61K 35/78 (TH); Nardo Zaias, Miami Beach, FL (52) U.S. Cl. ............................................ 424/450; 424/725 (US) (57) ABSTRACT Correspondence Address: Law Office of Eric G. Masamori Compositions and methods for administration of active 6520 Ridgewood Drive agents encapsulated within liposome beads to enable a wider Castro Valley, CA 94.552 (US) range of delivery vehicles, to provide longer product shelf life, to allow multiple active agents within the composition, (21) Appl. No.: 10/264,205 to allow the controlled use of the active agents, to provide protected and designable release features and to provide (22) Filed: Oct. 3, 2002 Visual inspection for damage and inconsistency. US 2003/0068365A1 Apr. 10, 2003 COMPOSITIONS AND METHODS FOR toxic degradation of the products, leakage of the drug from ADMINISTRATION OF ACTIVE AGENTS USING the liposome and the modifications of the Size and morphol LPOSOME BEADS ogy of the phospholipid liposome vesicles through aggre gation and fusion. Liposome vesicles are known to be CROSS REFERENCE TO OTHER thermodynamically relatively unstable at room temperature APPLICATIONS and can Spontaneously fuse into larger, leSS Stable altered liposome forms.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • China Japan United States Europe
    Inhibitor United States China Toll Free: +1 877 796-6397 Toll Free: 400-668-6834 Fax: +1 832 582-8590 Fax: 021-68591981 E-mail: [email protected] E-mail: [email protected] Europe Japan Tel: +49-89-46148500 Tel: + 81 3-5632-9610 Fax: +49-89-461485022 Fax: + 81 3-5632-9619 E-mail: [email protected] E-mail: [email protected] Protein Tyrosine Kinase PI3K/Akt/mTOR MAPK Inhibitors Cytoskeletal Signaling Selleck Chemicals supplies over 3,000 Apoptosis + inhibitors used in the study of cell 3000 Epigenetics Cell Cycle Inhibitors signaling pathways. Ubiquitin Signaling DNA Damage Stem Others Cells Neuronal Signaling Product Citations Selleck products have been cited in more than 12000 studies from various SCI journals. (Cell, Nature, Science: 61 studies) Compound Libraries Bioactive Compound Library 2659 compounds Nature. 2017, 541(7638):481-487. Nature. 2015, 521(7552):357-61. Science. 2016, 354(6315). Nature. 2017, 10.1038/nature21064. Nature. 2015, 521(7552):316-21. Science. 2016, 353(6302):929-32. Kinase Inhibitor Library Nature. 2016, 540(7631):119-123. Nature. 2015, 520(7549):683-7. Science. 2016, 352(6283):353-8. 430 inhibitors Nature. 2016, 539(7629):437-442. Nature. 2015, 520(7547):368-72. Science. 2016, 352(6282):189-96. Nature. 2016, 539(7628):304-308. Nature. 2015, 519(7543):370-3. Science. 2016, 351(6277):aad3680. FDA-approved Drug Library 1443 compounds Nature. 2016, 539(7627):54-58. Nature. 2015, 518(7538):254-7. Science. 2013, 341(6146):651-4. Nature. 2016, 538(7626):477-482. Nature. 2015, 517(7536):583-8.
    [Show full text]
  • Design Cosmetic Ingredients El Camp De Bossa - Les Tallades - La Figuerassa - El Pouet De Tomàs
    biogründl gründl bio biogründl factory Polígono Les Fallulles, nave 34 - sector 2 - 08620 Sant Vicenç dels Horts. Barcelona (SPAIN) Tel. +34 93 660 55 12 - Fax +34 93 660 55 13 - www.biogrundl.es biogründl station design cosmetic ingredients El Camp de Bossa - Les Tallades - La Figuerassa - El Pouet de Tomàs. Tarragona (SPAIN) biogründl factory Polígono Les Fallulles, nave 34 - sector 2 Sant Vicenç dels Horts Barcelona (SPAIN) biogründl station El Camp de Bossa, Les Tallades, La Figuerassa, El Pouet de Tomàs Tarragona (SPAIN) biogründl, s.l., a company located in Barcelona, whose activity is l+D+i and production in the field of active and auxiliary substances which are completely new for cosmetic industry. biogründl, s.l. was founded in 2002 being supported by a great human team with large technical and commercial experience. biogründl, s.l. is filling the gap in the area of cosmetic and dermatologic active substances, which was mainly the field for great sized companies engaged in the commercialization of many products involved in several fields of the chemical industry. Opposite to this concept, biogründl, s.l. has to do exclusively with substances destined to Cosmetology and Dermatology. biogründl, s.l. has acquired in 2012 ten Ha of land, biogründl station, in Tarragona (Spain), which is used to ecological plantation to obtain their own vegetable actives. This way, biogründl, s.l. ensures the origin and the obtaining of such actives. Its market strategy is based on the following concepts: • Contribution of new concepts in formulations to satisfy the proactive demands of Cosmetics. • Fast and dynamic response to customers’ need with the corresponding personal assistance.
    [Show full text]
  • EQUILIBRIUM-10 LINE the Authentic Expression of Balance in Your Skin
    01 EQUILIBRIUM-10 LINE The authentic expression of balance in your skin EQUILIBRIUM-10 LINE FIRST STEP TO BEAUTY Its effectiveness is immediate in the recovery of your skin’s optimum pH, and the balance of dry or oily skin. 01. Oxygenating The activity of cells receiving oxygen triples and cell division increased by 20%. 02. Restructuring increases cell activity, encouraging the elasticity of youthful skin. 03. Hydrating A balancing effect on the mantle, smoothing and closing pores. EQUILIBRIUM-10 LINE ACTIVE INGREDIENTS AQUAXTREM TM Placebo 25 AQUAXTREM™ 20 • Activates the own mechanisms of the skin for a long-lasting moisturization. + 11,6 % + 9,6 % • Skin hydration from the inside. 15 • Stratum corneum resistance and cohesion. • Improvement of barrier function and NMF. 10 • Complementary activity: anti-aging. % increase in hydration % increase in hydration 5 0 D29 D31 Increase of AQUAXTREM™ and placebo as compared to control WRINKLES CITRUSTEM™ Product T0 T56 % Decrease Placebo 3,58 3,47 3,17* • Organizes and redensifies dermis structure. CITRUSTEM™ (3%) 3,54 3,19 9,89* • Repairs extracelular matrix. CITRUSTEM™ (placebo) 3,54 3,19 6,7* • Result: Firmer skin. * Statistically significant (Wilcoxon, p<0.05) • Recovers the elasticity of 12 years ago. EQUILIBRIUM-10 LINE 01 BALANCING DERMO-PROTECTIVE FLUID ACTION It contains sweet almond oil and eucalyptus, which give it soothing, softening and anti-inflammatory properties. It cleanses and balances skins of all types, eliminating impurities and respecting the integrity of the epicutaneous mantle that protects the skin. HOW TO USE Apply the product with circular movements to clean the face and neck.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0183528A1 Maloney Et Al
    US 20100183528A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0183528A1 Maloney et al. (43) Pub. Date: Jul. 22, 2010 (54) ACNETREATMENT POWDER FOUNDATION Publication Classification (75)75) invenorInventors: Johnobtainstity. D. Malonev, Salisburv. NC (51) A61KInt. Cl. 8/368 (2006.01) Davidson NC (US) s A61O 1704 (2006.01) s A61O I/00 (2006.01) Correspondence Address: A6IP 7/10 (2006.01) INTELLECTUAL PROPERTY f TECHNOLOGY LAW (52) U.S. Cl. .......................................................... 424/60 PO BOX 14329 RESEARCH TRIANGLE PARK, NC 27709 (US) (57) ABSTRACT (73) Assignee: HARMONY LABORATORIES, Dry powder foundation formulations that include a sustained INC., Kannapolis, NC (US) release salicylic acid composition, an effective, buffering amount of one or more Salicylate ions, and one or more of Zinc (21) Appl. No.: 12/639,851 and titanium oxides, and pigments or colorants, are disclosed. 1-1. The formulations provide both acne treatment and preven (22) Filed: Dec. 16, 2009 tion, and Sunblock protection. The formulation can also O O include other Sunblocking or Sunscreen agents to prevent Related U.S. Application Data photoaging and Sunburn, such as avobenzone, and 3-ben (60) Provisional application No. 61/138.436, filed on Dec. Zophenone, and other cosmetically-acceptable active agents 17, 2008. and excipients. US 2010/0183528 A1 Jul. 22, 2010 ACNE TREATMENT POWDER FOUNDATION used as a foundation that provides both acne treatment and prevention and Sunblock protection. CROSS-REFERENCE TO RELATED 0007 Because the composition provides salicylic acid in APPLICATION the form of a Sustained-release composition, the salicylic acid remains effective for an extended period of time.
    [Show full text]
  • Fragances Extracts
    PERSONAL CARE extracts petroleum jellies and paraffins active ingredients antioxidants hair conditioners oils amino acids colourants emollients preservatives fragances vitamins emulsifiers fatty alcohols sunscreens multifunctionals waxes pearl shine concentrates moisturisers opacifiers At Escuder, we are specialists in distributing raw materials aimed primarily at the cosmetics, pharmaceutical, veterinary, food and dietary industries. Since 1896, our aim has been to provide the highest quality in our services and products. Escuder is a dynamic company, with a highly specialised team and all the necessary resources to constantly update our processes and incorporate new tools which enable us to establish close connections with our customers and suppliers. Our extensive experience, sound industry knowledge, reliability and professionalism allow us to adapt to our customers’ needs, providing the highest levels of quality and safety in managing the products and services we offer. This is our catalogue of products aimed primarily at the cosmetics industry. Here you will find a wide range of materials which we hope will be of interest to you and meet your needs. Actives 4-7 Amino Acids 7 Antibacterials, Antifungals 8 Antioxidants 8 Emollients 8-9 Emulsifiers / Fatty Alcohols 10-11 Exfoliants 11 Extracts 12 Fragrances 12 Hair Conditioners 13 Humectants 14 Oils 14-15 Pearl Shine Concentrates / Opacifiers 15 Ph Regulators 15 Preservatives 16 Rheological Modifiers 17 Sequestrant Agents 17 Solubilizers 17 Sunscreen Filters 18 Surfactants 18-19 Sweeteners
    [Show full text]
  • High-Value Oxy-Pharmaceuticals from P450 BM3 ‘Gatekeeper’ Mutations
    High-value oxy-pharmaceuticals from P450 BM3 ‘gatekeeper’ mutations A thesis submitted to The University of Manchester for the degree of Doctor of Philosophy in the Faculty of Science and Engineering 2018 Laura N. Jeffreys School of Chemistry BLANK PAGE 2 Table of Contents Figures……. ………………………………………………………………………………..8 Tables……………………………………………………………………………………...10 Supplementary Figures………………………………………………………………….. 11 List of Abbreviations…………………………………………………………………….. 13 Abstract…………………………………………………………………………………... 15 Acknowledgements ………………………………………………………………………16 Declaration……………………………………………………………………………….. 17 Copyright Statement…………………………………………………………………….. 18 Preface to the Journal Format Thesis………………………………………………….. 19 Author contributions……………………………………………………………………. 21 Chapter 1: General Introduction……………………………………………………... 23 1.1. An Overview of Cytochromes P450……………………………………... 23 1.1.1. The Evolution and Nomenclature of Cytochromes P450…………….23 1.1.2. The History of Cytochrome P450 Research ………………………….28 1.1.3. The P450 Catalytic Cycle …………………………………………….32 1.1.4. The Structure of P450 Enzymes ……………………………………...38 1.1.5. Unusual P450 Proteins ……………………………………………….43 1.2. The Natural Fusion Protein P450 BM3 (CYP102A1) ……………………47 1.2.1. The Structure of P450 BM3 ………………………………………….48 1.2.2. Electron Transfer Within P450 BM3 ………………………………...54 1.2.3. P450 BM3 Mutagenesis and the Gatekeeper Mutants ……………….58 1.3. Real-World Applications of P450 Enzymes ……………………………...61 1.3.1. Using P450 BM3 in the Pharmaceutical Industry ……………………63 1.3.2. Using other P450
    [Show full text]